Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Branka Radic-Sarikas

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cells|April 25, 2020
The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma PathogenesisHeinrich Kovar, Lisa Bierbaumer, Branka Radic-Sarikas
Cells|April 23, 2022
Zooming in on Long Non-Coding RNAs in Ewing Sarcoma PathogenesisDave N T Aryee, Valerie Fock, Utkarsh Kapoor, et al.
Molecular Therapy. Oncology|June 12, 2026
Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibitionBranka Radic-Sarikas, Marica Markovic, Martha Magdalena Zylka, et al.
Scientific Reports|June 10, 2017
Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporterBranka Radic-Sarikas, Melinda Halasz, Kilian V M Huber, et al.
Molecular Therapy. Oncology|March 20, 2026
Differential immune infiltrates in histomorphologic Wilms tumor regions identify prognostic macrophagesLukas Watzke, Francesca Palmisani, Maud Plaschka, et al.
Cell Reports|March 13, 2025
YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cellsRahil Noorizadeh, Barbara Sax, Tahereh Javaheri, et al.
Molecular Cancer Therapeutics|January 8, 2017
Combinatorial Drug Screening Identifies Ewing Sarcoma-specific SensitivitiesBranka Radic-Sarikas, Kalliopi P Tsafou, Kristina B Emdal, et al.
Oncogenesis|January 9, 2021
YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cellsLisa Bierbaumer, Anna M Katschnig, Branka Radic-Sarikas, et al.
Oncotarget|August 21, 2018
Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducersKalliopi Tsafou, Anna Maria Katschnig, Branka Radic-Sarikas, et al.
Cancer Letters|December 3, 2022
High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-X<sub>L</sub> inhibition against Ewing sarcomaSarah Grissenberger, Caterina Sturtzel, Andrea Wenninger-Weinzierl, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cells|April 25, 2020
The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma PathogenesisHeinrich Kovar, Lisa Bierbaumer, Branka Radic-Sarikas
Cells|April 23, 2022
Zooming in on Long Non-Coding RNAs in Ewing Sarcoma PathogenesisDave N T Aryee, Valerie Fock, Utkarsh Kapoor, et al.
Molecular Therapy. Oncology|June 12, 2026
Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibitionBranka Radic-Sarikas, Marica Markovic, Martha Magdalena Zylka, et al.
Scientific Reports|June 10, 2017
Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporterBranka Radic-Sarikas, Melinda Halasz, Kilian V M Huber, et al.
Molecular Therapy. Oncology|March 20, 2026
Differential immune infiltrates in histomorphologic Wilms tumor regions identify prognostic macrophagesLukas Watzke, Francesca Palmisani, Maud Plaschka, et al.
Cell Reports|March 13, 2025
YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cellsRahil Noorizadeh, Barbara Sax, Tahereh Javaheri, et al.
Molecular Cancer Therapeutics|January 8, 2017
Combinatorial Drug Screening Identifies Ewing Sarcoma-specific SensitivitiesBranka Radic-Sarikas, Kalliopi P Tsafou, Kristina B Emdal, et al.
Oncogenesis|January 9, 2021
YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cellsLisa Bierbaumer, Anna M Katschnig, Branka Radic-Sarikas, et al.
Oncotarget|August 21, 2018
Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducersKalliopi Tsafou, Anna Maria Katschnig, Branka Radic-Sarikas, et al.
Cancer Letters|December 3, 2022
High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-X<sub>L</sub> inhibition against Ewing sarcomaSarah Grissenberger, Caterina Sturtzel, Andrea Wenninger-Weinzierl, et al.
Pageof 2